The GIGYF1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from the Raji B?lymphocyte line, with disruption of the GIGYF1 gene encoding a translation repressor. This heterogeneous cell pool enables loss?of?function studies without the clonal biases inherent in single?cell?derived knockout lines, reflecting a more physiologically relevant mixture of genotypes. The knockout model is generated via targeted CRISPR/Cas9-mediated gene disruption, resulting in a polyclonal population suitable for investigating translational control mechanisms in human B cells.
The Raji cell line is an Epstein?Barr virus (EBV)-positive Burkitt??s lymphoma B?lymphocyte model widely used to study adaptive immunity, B?cell biology, and lymphomagenesis. Raji cells retain key features of mature B lymphocytes, including immunoglobulin expression and responsiveness to growth and survival signals, making them a valuable platform for examining how post?transcriptional regulation impacts B?cell function and malignant transformation. The EBV?driven background also provides a context for dissecting viral?host interactions that modulate translation.
GIGYF1 functions as a translational repressor by bridging the 4EHP (eIF4E2) cap?binding complex and the GRB10 adaptor protein, thereby inhibiting initiation of a subset of mRNAs involved in growth and metabolism. This repressor activity is modulated by the insulin/IGF signaling axis: following activation of INSR/IGF1R, IRS1 recruits and activates PI3K, leading to AKT?mediated phosphorylation events that relieve GIGYF1?dependent repression. The mTORC1 pathway converges on analogous translational control nodes, positioning GIGYF1 at the intersection of nutrient and growth factor signaling. Key interacting factors include GRB10, eIF4E2, and eIF4G, while downstream targets encompass growth?related transcripts whose translation is derepressed upon GIGYF1 loss.
In Raji B cells, knockout of GIGYF1 is predicted to lift translational repression on mRNAs that promote proliferation and survival, potentially enhancing growth signaling and altering apoptotic thresholds. This model is particularly relevant for understanding how dysregulation of translational control contributes to B?cell malignancies such as Burkitt??s lymphoma, as well as for dissecting the role of insulin/IGF pathway components in lymphocyte biology. Moreover, GIGYF1 mutations have been implicated in neurodevelopmental disorders including autism spectrum disorder and intellectual disability, and genetic variation is associated with type 2 diabetes; thus, these polyclonal knockout cells offer a tractable system for modeling disease?relevant molecular mechanisms in an immune cell context.
Researchers can employ the GIGYF1 Knockout Raji Polyclonal Cells for a range of functional assays, including Western blotting and RT?qPCR to confirm downstream target expression changes, polysome profiling to assess global translation shifts, and proliferation or apoptosis assays to evaluate growth phenotypes. Flow cytometry can be used to monitor B?cell surface markers under various stimulatory conditions. These applications support studies in translational control, insulin/IGF signaling in adaptive immunity, metabolic disease modeling, and lymphoma biology. For further information or to inquire about custom applications, please contact Ascent Research.
